Fig. 4

MAP17 expression predicts sensitivity to erlotinib in lung adenocarcinoma. a Erlotinib sensitivity in lung adenocarcinoma cell lines based on MAP17 mRNA expression. b Erlotinib sensitivity in one MAP17-overexpressing and one MAP17-silenced lung adenocarcinoma cell lines. c Analysis of sensitivity to different EGFR inhibitors in lung adenocarcinoma cell lines based on MAP17 expression using data from the GDSC database. Determination of MAP17 expression (d) and EGFR activation (e) in lung adenocarcinoma PDXs. (F) Tumour growth assessment in erlotinib-treated adenocarcinoma PDXs with differential MAP17 expression. g Response to erlotinib or gefitinib treatment in adenocarcinoma patients (Additional file 1: Table S3) with tumours harbouring low or high MAP17 mRNA expression. Expression was considered as high with values above the median value (left) or the 75th percentile (right)